Is propofol safe when administered to cirrhotic patients during sedative endoscopy?

Abstract

Background/aims: In patients with liver cirrhosis, drugs acting on the central nervous system can lead to hepatic encephalopathy and the effects may be prolonged. Recently, misuse of propofol has been reported and the associated risk of death have become an issue. Propofol is commonly used during sedative endoscopy; therefore, its safety in high-risk groups must be further investigated. We performed a pilot study of the safety and efficacy of propofol during endoscopy in Korean patients with cirrhosis.

Methods: Upper gastrointestinal endoscopy was performed under sedation with propofol along with careful monitoring in 20 patients with liver cirrhosis and 20 control subjects. The presence or development of hepatic encephalopathy was assessed using the number connection test and neurologic examination.

Results: Neither respiratory depression nor clinically significant hypotension were observed. Immediate postanesthetic recovery at 5 and 10 minutes after the procedure was delayed in the cirrhotic patients compared with the control group; however, at 30 minutes, the postanesthetic recovery was similar in both groups. Baseline psychomotor performance was more impaired in cirrhotic patients, but propofol was not associated with deteriorated psychomotor function even in cirrhotic patients with a minimal hepatic encephalopathy.

Conclusions: Sedation with propofol was well tolerated in cirrhotic patients. No newly developed hepatic encephalopathy was observed.

Keywords: Hepatic encephalopathy; Liver cirrhosis; Propofol; Sedative endoscopy.

Figure 1

The levels of aminotransferases did not change signif icantly after the procedure in the cirrhotic group. Serum bilirubin levels were not elevated. AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Figure 2

The mean visual analogue scale score was significantly lower in the cirrhotic group.